Tradjenta (linagliptin) costs roughly $555 to $570 for a 30-day supply at U.S. pharmacies, working out to about $14.48 per tablet. That price tag makes it one of the more expensive options for managing type 2 diabetes, especially when older medications like metformin cost as little as $64 per year. Several factors drive that price, and understanding them can help you decide whether to stick with Tradjenta or explore alternatives.
No Generic Version Is Available Yet
The single biggest reason Tradjenta costs so much is that Boehringer Ingelheim, the company that makes it, still holds active patents on the drug. While some of the original patents expired as early as 2023 and 2025, several newer patents extend protection through 2029 and as far out as March 2031. As long as those patents hold, no competing manufacturer can sell a generic version of linagliptin in the United States.
Dr. Reddy’s Laboratories received tentative FDA approval for a generic linagliptin tablet back in 2021, but “tentative” approval means the product met all quality and safety standards without being allowed to launch. The company filed legal certifications challenging some of the later patents as invalid or not infringed, but until those challenges succeed or the patents expire, generic competition remains blocked. When a generic does eventually reach the market, prices typically drop 80% or more within a few years.
A Unique Feature Justifies Premium Positioning
Tradjenta belongs to a class of diabetes drugs called DPP-4 inhibitors, which help your body produce more insulin after meals. Several other drugs in this class exist, but Tradjenta has one pharmacological distinction that its manufacturer leans on: it’s eliminated from the body almost entirely through the gut rather than the kidneys. Every other DPP-4 inhibitor requires dose adjustments when kidney function declines.
That matters because kidney disease is extremely common in people with type 2 diabetes. Tradjenta can be prescribed at the same dose regardless of how well your kidneys are working, with no monitoring or adjustments needed. This convenience gives Boehringer Ingelheim a clinical rationale for pricing the drug above competitors, even though the actual blood sugar lowering effect is comparable to other DPP-4 inhibitors.
U.S. Prices Dwarf International Costs
The price gap between the U.S. and the rest of the world is staggering. At American pharmacies, 90 tablets of Tradjenta 5 mg costs around $1,300. The same quantity from international pharmacies accredited by PharmacyChecker starts at $62, roughly $0.69 per tablet. That’s a 95% difference. In the UK, the drug is sold under the slightly different name “Trajenta” (without the “d”) at similarly low prices.
This disparity exists because most other countries negotiate drug prices at a national level or set price ceilings. The U.S. has historically allowed manufacturers to set their own list prices, and pharmacy benefit managers negotiate rebates behind the scenes that rarely translate into lower costs at the register for uninsured or underinsured patients.
Insurance Coverage Varies Widely
If you have Medicare Part D, Tradjenta may be covered, but your out-of-pocket cost depends heavily on your plan’s formulary. Some Medicare Advantage plans, like Aetna’s 2025 formulary, do cover Tradjenta with a quantity limit of 30 tablets per 30 days, though it’s typically placed on a preferred brand or non-preferred brand tier, meaning higher copays than generics. Many commercial insurance plans require prior authorization or step therapy, meaning you’d need to try a cheaper drug first and show it didn’t work before they’ll cover Tradjenta.
Without insurance, you’re facing the full list price. Manufacturer savings cards can reduce the cost for commercially insured patients, but these programs usually exclude Medicare, Medicaid, and other government-funded plans.
Lower-Cost Alternatives Worth Discussing
If Tradjenta’s price is a barrier, several effective alternatives cost a fraction of the price. The most obvious is metformin, which remains the first-line treatment for type 2 diabetes and costs between $64 and $86 per year in generic form. Sulfonylureas like glyburide run as low as $12 to $84 annually, and generic pioglitazone costs $267 to $625 per year.
If your doctor specifically wants you on a DPP-4 inhibitor, other options in the same class may be available at lower cost depending on your insurance formulary, though none currently have a generic in the U.S. either. The key question to ask is whether you actually need Tradjenta’s kidney-friendly dosing advantage. If your kidney function is normal, a different DPP-4 inhibitor or drug class could work just as well for significantly less money.
For people with kidney disease who genuinely benefit from linagliptin’s unique profile, newer drug classes like SGLT2 inhibitors offer both blood sugar control and kidney protection, and some now have generic versions entering the market. Your prescriber can help weigh the clinical tradeoffs against cost.